Effects of 40 Hz audio-visual stimulation and cognitive games on Alzheimer's disease
Development of a Sensory Entrainment-Integrated Cognitive Game Kit to Improve Cognitive Functions in Alzheimer's Disease
This study is testing a new app that combines sound and light with brain games to see if it can help improve thinking skills in people with early to middle-stage Alzheimer's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 60 Years to 86 Years |
| Sex | All |
| Sponsor | Istanbul Medipol University Hospital Academic / other |
| Locations | 1 site (Istanbul, Beykoz) |
| Trial ID | NCT06595511 on ClinicalTrials.gov |
What this trial studies
This project aims to develop a digital application that combines 40 Hz audio-visual stimulation with cognitive games to monitor and potentially improve cognitive function in patients with Alzheimer's disease. The study will recruit early and middle-stage Alzheimer's patients aged 60 to 75, who will use the application for one hour a day over three months. Participants will be assessed through neurological examinations, neuropsychological tests, and EEG recordings to evaluate cognitive functions. The study will compare outcomes between those using the application, those not receiving treatment, and healthy controls.
Who should consider this trial
Good fit: Ideal candidates for this study are early to middle-stage Alzheimer's patients aged 60 to 75 who meet specific cognitive impairment criteria.
Not a fit: Patients with other types of dementia or significant mental health disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-pharmacological method to enhance cognitive function and slow the progression of Alzheimer's disease.
How similar studies have performed: While the combination of sensory entrainment and cognitive games is innovative, similar approaches have shown promise in enhancing cognitive function in other populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion and Exclusion Criteria for Alzheimer Patients: Inclusion Criteria: * Diagnosed with AD according to DSM-IV and NINCDS-ADRDA criteria, * Impaired activities of daily living, * Having a CDR score of 1-2 and an SMMT score of 15-26, * Stable use of psychoactive medications, including acetylcholinesterase inhibitors or other medications that enhance cognitive functions, * Individuals aged 60-86 with at least 5 years of education. Exclusion Criteria: * Having frontotemporal dementia, vascular dementia, Lewy body dementia or other types of dementia, * Parkinsonism, clinical depression, other mental disorders, epilepsy, drug addiction, alcohol addiction, and traumatic brain injury Inclusion and Exclusion Criteria of Healthy Older Adults: Inclusion criteria: * Between the ages of 60-86 * Without any neurological abnormalities or general cognitive impairment (MMSE above 25), * Not diagnosed with a neurological and/or psychiatric disease, * Not using neurological and/or psychiatric medication Exclusion criteria * Having clinical signs of cognitive impairment, such as mild cognitive impairment, Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, etc. * Epilepsy, alcohol and/or drug addiction, use of medications that affect cognitive functions, and traumatic brain injury
Where this trial is running
Istanbul, Beykoz
- Istanbul Medipol University — Istanbul, Beykoz, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Bahar Güntekin, PhD
- Email: bguntekin@medipol.edu.tr
- Phone: +90 5326031560
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.